KALA BIO, Inc. (KALA): Nasdaq/NYSE listing notice — KALA BIO receives Nasdaq bid price deficiency notice; 180-day compliance period until July 20, 2026

KALA BIO, Inc.

Letter dated Jan 20, 2026; closing bid price below $1.00 for 30 consecutive business days (Dec 3, 2025–Jan 16, 2026).
Must maintain closing bid price ≥$1.00 for at least ten consecutive business days during the compliance period to regain compliance.
If not cured by July 20, 2026, may be eligible for an additional 180-day period if other Nasdaq listing standards are met.
No immediate impact on stock listing; shares continue trading on Nasdaq subject to other requirements.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

KALA BIO, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 20, 2026, KALA Bio, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between December 3, 2025, to January 16, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market (“ Nasdaq ”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or unti

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-26-000502

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.